Related Party

9 Months Ended

Sep. 30, 2013

2.	Related Party

Based on its stock ownership in the Company, MD Anderson Cancer Center meets the criteria to be deemed a related party of Bio-Path Holdings. For the quarters ending September 30, 2013 and 2012, MD Anderson related party research and development expense was $15,000 and $47,582, respectively. MD Anderson related party research and development expense for the quarter ending September 30, 2013 was comprised of MD Anderson clinical trial hospital expense of $15,000. As of September 30, 2013 accrued expense related party was $52,050 for MD Anderson clinical trial hospital expense and accrued license payments related party of $50,000 for past patent expenses (See Notes 4., 5. and 6.). For the quarter ending September 30, 2012 related party research and development expense consisted of $39,000 for expenses for treating patients in the Company’s clinical trial and $8,582 for patent expenses. As of September 30, 2012, the Company had accrued expense of $39,000 for clinical trial expense for the related party, $8,582 in related party accounts payable and $50,000 in accrued license payments payable due to the related party for past patent expenses for the Company’s Technology License. See Notes 5 and 6.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References+ Details